Welcome to







. , .pdf-, . . , . , , . e-mail. , , . , : (495) 730-63-51 e-mail: atm-press2012@yandex.ru



-




  

2018 / N 1


.. , .. , ..

References
1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinsons disease: a review of the evidence. European Journal of Epidemiology 2011 Jun;26(Suppl 1):S1-58.
2. Peine A, Faulkner A, Jaeger B, Moors E. Science, technology and the grand challenge of aging understanding the socio-material constitution of later life. Technological Forecasting and Social Change 2015;93:1-9.
3. Olanow CW, Schapira AHV. Therapeutic prospects for Parkinson disease. Annals of Neurology 2013 Sep;74(3):337-47.
4. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nature Reviews Disease Primers 2017 Mar;3:17013.
5. Extrapyramidal disorders. Guidelines for the diagnosis and treatment. Shtock VN, Ivanova-Smolenskaya IA, Levin OS, editors. Moscow: MEDpress-inform; 2002. 608 p. (In Russian).
6. Guidelines for the diagnosis and treatment of Parkinsons disease. Illarioshkin SN, Levin OS, editors. Moscow: MEDpress-inform; 2016. 366 p. (In Russian).
7. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. Journal of Neurology 2000 Apr;247(Suppl 2):II43-50.
8. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Archives of Neurology 2006 Dec;63(12):1756-60.
9. Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, Brooks D. Parkinsons disease the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. Journal of Parkinsons Disease. 2013;3(11):1-11.
10. Illarioshkin SN. Course of Parkinsons disease and approaches to early diagnosis. In: Parkinsons disease and movement disorders. Guidance for doctors. Proceedings of II National Congress on Parkinsons disease and movement disorders (with international participation). Illariushkin SN, Levin OS, editors. Moscow: 2011:41-7 (In Russian).
11. Picconi B, Calabresi P. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease? Movement Disorders 2014 May;29(6):715-9.
12. Lysogorskaya EV, Klyushnikov SA. Application points for biological drugs in therapy of neurodegenerative diseases. Nervous diseases 2015;2:10-3 (In Russian)
13. Teng KK, Felice S, Kim T, Hempstead BL. Understanding proneurotrophin actions: recent advances and challenges. Developmental Neurobiology 2010 Apr;70(5):350-9.
14. Gomazkov OA. Neurotrophic and growth factors of the brain: regulatory specifity and therapeutic potential. Advances in Physiology Sciences 2005;2:22-40 (In Russian).
15. Dechant G, Neumann H. Neurotrophins. Advances in Experimental Medicine and Biology 2002;513:303-34.
16. Barde YA. Neurotrophins: a family of proteins supporting the survival of neurons. Progress in Clinical and Biological Research 1994;390:45-56.
17. Beletskiy IP, Moshnikova AB, Prusakova OV. Cytotoxic signal transmission pathways via TNF family receptors. Biochemistry (Moscow) 2002;67(3):377-95 (In Russian).
18. Galoyan AA. Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochemistry (Moscow) 2001;2:83-95 (In Russian).
19. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes & Development 2000 Dec;14(23):2919-37.
20. Friedman WJ. Proneurotrophins, seizures, and neuronal apoptosis. Neuroscientist 2010 Jun;16(3):244-52.
21. Illarioshkin SN. Conformational diseases of the brain. Moscow: Yanus-K; 2003. 248 p. (In Russian).
22. Allen SJ, Watson JJ, Shoemark DK. Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & Therapeutics 2013 May;138(2):155-75.
23. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260(5111):1130-2.
24. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, Elsberry DD, Klein MC, Gerhardt GA, Gash DM. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002 Oct;125(Pt 10):2191-201.
25. Smith AD, Kozlowski DA, Bohn MC, Zigmond MJ. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Experimental Neurology 2005 Jun;193(2):420-6.
26. Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M.Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinsons disease. Neurobiology of Disease 2006 Jan;21(1):90-101.
27. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Human Gene Therapy 2009 May;20(5):511-8.
28. Herzog CD, Dass B, Gasmi M. Bakay R, Stansell JE, Tuszynski M, Bankiewicz K, Chen EY, Chu Y, Bishop K, Kordower JH, Bartus RT. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Molecular Therapy 2008 Oct;16(10):1737-44.
29. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinsons disease: a double-blind, randomised, controlled trial. The Lancet Neurology 2010 Dec;9(12):1164-72.
30. Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinsons disease. Neurobiology of Disease 2011 Dec;44(1):38-52.
31. Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinsons disease. Movement Disorders 2013 Jan;28(1):96-109.
32. Lindholm P, Voutilainen MH, Laurén J. Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T, Tuominen RK, Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007;448(7149):73-7.
33. Airavaara M, Voutilalainen MH, Wang Y, Hoffer B. Neurorestoration. Parkinsonism & Related Disorders 2012 Jan;18(Suppl 1):S143-6.
34. Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinsons disease. Experimental Neurology 2011 Mar;228(1):99-108.
35. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B, Wang Y. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplantation 2012;21(6):1213-23.
36. Lad SP, Neet KE, Mufson EJ. Nerve growth factor: structure, function and therapeutic implications for Alzheimers disease. Current Drug Targets. CNS and Neurological Disorders 2003 Oct;2(5):315-34.
37. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntingtons disease. Progress in Neurobiology 2007 Apr;81(5-6):294-330.
38. Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004 Jun;118(1):127-38.
39. La Spada AR, Weydt P, Pineda VV. Huntingtons disease pathogenesis: mechanisms and pathways. In: Neurobiology of Huntingtons disease: applications to drug discovery. Lo DC, Hughes RE, editors. Boca Raton, FL: CRC Press/Taylor & Francis; 2011: Chapter 2.
40. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín-Ibañez R, Muñoz MT, Mengod G, Ernfors P, Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntingtons disease. Journal of Neuroscience 2004 Sep;24(35):7727-39.
41. Niu S, Zhang LK, Zhang L, Zhuang S, Zhan X, Chen WY, Du S, Yin L, You R, Li CH, Guan YQ. Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinsons disease model. Theranostics 2017 Jan;7(2):344-56.
42. Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-Iqbal I. The dentate gyrus neurogenesis: a therapeutic target for Alzheimers disease. Acta Neuropathologica 2003 Mar;105(3):225-32.
43. Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimers disease. Acta Neuropathologica 2007 Mar;113(3):265-75.
44. Gromova OA, Kudrin AV. New facets of molecular pharmacology of natural neurotrophic agents. Trace elements as a component of neuroprotective ligands (review). International Medical Journal 2011;5:441-5 (In Russian).
45. Gromova OA, Torshin IYu, Gogoleva IV, Pronin AV, Stelmashuk EV, Isaev NK, Genrikhs EE, Demidov VI, Volkov AYu, Khaspekov GL, Aleksandrova OP. Pharmacokinetic and pharmacodynamic synergism between neuropeptides and lithium in the neurotrophic and neuroprotective action of cerebrolysin. SS Korsakov Journal of Neurology and Psychiatry 2015;11(3-1):65-72 (In Russian).
46. Torshin IYu, Gromova OA. Expert data analysis in molecular pharmacology. Moscow: MTsNMO; 2012. 747 p. (In Russian).
47. Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiology of Aging 2007 Aug;28(8):1148-62.
48. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. Journal of Neural Transmission (Vienna) 2001;108(4):459-73.
49. Gromova OA, Pronin AV, Torshin IYu, Kalacheva AG, Grishina TR. Neurotrophic and antioxidant potential of neuropeptides and trace elements. Neurology, Neuropsychiatry, Psychosomatics 2015;7(4):92-100 (In Russian).
50. Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of Neuroscience Research 2010 Nov;88(15):3275-81.
51. Chen CC, Wei ST, Tsaia SC. Chen XX, Cho DY. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study. British Journal of Neurosurgery 2013 Dec;27(6):803-7.
52. Zhang Y, Chopp M, Meng Y, Zhang ZG, Doppler E, Mahmood A, Xiong Y. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. Journal of Neurosurgery 2013 Jun;118(6):1343-55.
53. Formichi P, Radi E, Battisti C. Di Maio G, Dotti MT, Muresanu D, Federico A. Effects of cerebrolysin administration on oxidative stress-induced apoptosis in lymphocytes from CADASIL patients. Neurological Sciences 2013 Apr;34(4):553-6.
54. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. The Cochrane Database of Systematic Reviews 2013 Jan;(1):CD008900.
55. Gromova OA, Torshin IYu, Gogoleva IV. Mechanisms of neurotrophic and neuroprotective effects of cerebrolysin in cerebral ischemia. SS Korsakov Journal of Neurology and Psychiatry 2014;114(3-1):43-50 (In Russian).
56. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barcelona, Spain: 1998) 2012 Apr;48(Suppl A):3-24.
57. Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick C, Adame A, Fahnestock M, Doppler E, Novak P, Moessler H, Masliah E. Cerebrolisin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimers disease. Journal of Neuroscience Research 2013 Feb;91(2):167-77.
58. Gauthier S, Proaño JV, Jia J. Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimers disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders 2015;39(5-6):332-47.
59. Gavrilova SI, Zharikov GA. Modern strategy of pathogenetic therapy of Alzheimers disease. Annals of the Russian Academy of Medical Sciences 2001;7:13-8 (In Russian).
60. Moessler H. New data on cerebrolysin: evidence-based effectiveness. Pharmateca 2007;6:33-42 (In Russian).
61. Wenzel E. The effect of cerebrolysin on chronic encephalopathy. An experimental psychological and electroencephalographic study (authors translation). Münchener Medizinische Wochenschrift 1976;118(45):1473-6.
62. Noor NA, Mohammed HS, Mourad IM, Khadrawy YA, Aboul Ezz HS. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinsons disease. Life Sciences 2016 Jun;155:174-9.
63. Ahmed H, Salem A, Atta H, Ghazy M, Aglan H. Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinsons disease in rat model? Human & Experimental Toxicology 2014 Dec; 33(12):1217-31.
64. Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opinion on Investigational Drugs 2000 Apr;9(4):747-64.
65. Lukhanina EP, Karaban IN, Burenok YuA, Melnik NA, Berezetskaya NM. Effect of cerebrolysin treatment on the electroencephalographic indices of brain activity in Parkinsons disease. SS Korsakov Journal of Neurology and Psychiatry 2004;104(7):54-60 (In Russian).
66. Subrt O. Therapeutic experience with Cerebrolysin in severe akinetic form of Parkinsons disease. In: Proceedings of III Symposium on Cerebrolysin; 1991 May 21; Moscow. Moscow, 1991:71-80.
  

[ N 1 | | ]